Drugs / recombinant vaccinia-B7.1 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00020254 | Jun 2000 → Oct 2004 | prostate cancer | National Cancer Institute (NCI) | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant vaccinia-B7.1 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00020254 ↗ |
| Modality | Vaccine | “The vaccine consisted of recombinant vaccinia viruses containing the PSA and B7.1 costimulatory genes as prime vaccinations” PMID 16006888 ↗ Aug 2005 |
| Route | Subcutaneous | “vaccine containing recombinant vaccinia-prostate-specific antigen (PSA) and rV-B7.1 subcutaneously (SC) on day 2 only” NCT00020254 ↗ |